Ethic Inc. purchased a new stake in shares of Repligen Co. (NASDAQ:RGEN) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 1,407 shares of the biotechnology company’s stock, valued at approximately $281,000.
Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Van ECK Associates Corp lifted its position in shares of Repligen by 4.1% during the 2nd quarter. Van ECK Associates Corp now owns 3,453 shares of the biotechnology company’s stock valued at $689,000 after buying an additional 137 shares during the last quarter. Aigen Investment Management LP purchased a new position in shares of Repligen during the 2nd quarter valued at $287,000. Citigroup Inc. lifted its position in shares of Repligen by 125.1% during the 2nd quarter. Citigroup Inc. now owns 19,371 shares of the biotechnology company’s stock valued at $3,866,000 after buying an additional 10,764 shares during the last quarter. O Shaughnessy Asset Management LLC lifted its position in shares of Repligen by 38.8% during the 2nd quarter. O Shaughnessy Asset Management LLC now owns 723 shares of the biotechnology company’s stock valued at $144,000 after buying an additional 202 shares during the last quarter. Finally, Knowledge Leaders Capital LLC purchased a new position in shares of Repligen during the 2nd quarter valued at $580,000. 83.82% of the stock is currently owned by hedge funds and other institutional investors.
Shares of RGEN opened at $306.90 on Friday. The stock has a market capitalization of $16.85 billion, a price-to-earnings ratio of 171.45 and a beta of 0.90. The stock’s 50-day simple moving average is $254.76 and its 200 day simple moving average is $215.50. Repligen Co. has a 52-week low of $138.00 and a 52-week high of $310.69.
A number of brokerages have recently commented on RGEN. Craig Hallum upped their price target on Repligen from $251.00 to $258.00 and gave the company a “buy” rating in a research report on Wednesday, July 28th. KeyCorp increased their price objective on Repligen from $255.00 to $335.00 and gave the stock an “overweight” rating in a report on Friday. Finally, Stephens increased their price objective on Repligen from $255.00 to $290.00 and gave the stock an “overweight” rating in a report on Friday, August 20th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $262.17.
In other news, VP Ralf Kuriyel sold 4,001 shares of the stock in a transaction dated Monday, August 30th. The stock was sold at an average price of $282.13, for a total transaction of $1,128,802.13. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Karen A. Dawes sold 4,585 shares of the stock in a transaction dated Tuesday, July 20th. The shares were sold at an average price of $202.09, for a total value of $926,582.65. The disclosure for this sale can be found here. Insiders sold a total of 52,154 shares of company stock worth $14,144,680 over the last 90 days. Corporate insiders own 1.20% of the company’s stock.
Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs.
Featured Article: 52-Week High/Low Prices For Stock Selection
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.